Can Immutep Limited convert orphan designation into a credible late-stage oncology program?
FDA orphan drug designation gives Immutep Limited a new sarcoma pathway. Find out why eftilagimod alfa could reshape its oncology strategy.
Why the TACTI-004 Phase III outcome challenges assumptions about LAG-3 immune activation
Immutep Limited halts its TACTI-004 lung cancer trial after a futility analysis. Discover what the setback means for eftilagimod alfa and LAG-3 immunotherapy.